A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR 3201 Injection in Healthy Participants
A Randomized, Double Blind, Dose Escalation, Placebo Controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Intravenous and Subcutaneous Administrations of SHR 3201 Injection in Healthy Participants
This study is a randomized, double-blind, dose-escalation, placebo-controlled Phase I clinical trial in healthy participants to evaluate the safety, tolerability, and pharmacokinetics of single intravenous and subcutaneous administrations of SHR-3201.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Yifei He, PhD.
- Phone Number: +86-0518-82342973
- Email: yifei.he.yh91@hengrui.com
Study Contact Backup
- Name: Yuanyuan Huang, PhD.
- Phone Number: +86-0518-82342973
- Email: yuanyuan.huang@hengrui.com
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230000
- Recruiting
- The First Affiliated Hospital of University of Science and Technology of China
-
Principal Investigator:
- Jiong Shi
-
Principal Investigator:
- Zhaoyi Yang
-
Contact:
- Jiong Shi
- Email: jshi2022@ustc.edu.cn
-
Contact:
- Zhaoyi Yang
- Phone Number: +86-551-65997421
- Email: young2382@ustc.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male or female participants aged 18 to 60 years (inclusive) at the time of informed consent signing;
- Male participants weighing ≥ 50.0 kg, and female participants weighing ≥ 45.0 kg, with a body mass index (BMI) between 19.0 and 28.0 kg/m² (inclusive), where BMI = weight (kg) / height² (m²);
- Female participants of child bearing potential shall agree to contraception and oocyte donation avoidance from ICF signature to 6 months after last investigational product dose, with negative serum pregnancy tests at screening and baseline. Male participants shall agree to highly effective contraception and sperm donation avoidance from ICF signature to 6 months after last investigational product dose;
- Ability to understand the study procedures and requirements, willingness to participate voluntarily, and provide written informed consent.
Exclusion Criteria:
- Participants with past or current acute or chronic disorders of the circulatory, endocrine, nervous, digestive, respiratory, hematological, immunological, psychiatric systems or metabolic abnormalities, as assessed by the Investigator to be unsuitable for study enrollment;
- Have a history of drug or other allergies, or, in the investigator's judgment, may be allergic to the investigational product or any of its components;
- Have undergone major surgery within 6 months prior to screening, or have undergone surgery that may significantly affect the in vivo disposition of the investigational product or the safety evaluation, or plan to undergo surgery during the trial period;
- Have participated in any clinical trial as a participant within 3 months prior to Screening, or plan to participate in other clinical trials during the course of this study;
- Have experienced blood loss or donated blood > 400 mL (excluding menstrual blood loss in females), received blood transfusion or blood products within 3 months prior to Screening, or plan to donate blood during the trial or within 1 month after the end of the trial;
- Cannot tolerate MRI or have MRI contraindications, including but not limited to cardiac pacemaker, defibrillator, artificial heart valve or other metallic implants; or other conditions assessed by the Investigator that may cause potential risks during MRI scanning;
- Have any laboratory abnormalities at screening, or have clinically significant abnormalities in vital signs, physical examinations, or laboratory tests specified in the protocol as judged by the investigator;
- Have chest X-ray (posteroanterior view) or abdominal ultrasound findings at Screening judged by the investigator to be clinically significant abnormalities;
- Have positive results at Screening for any of the following: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), or Treponema pallidum antibody (Anti-TP);
- Have used or are currently using any prescription drugs or over-the-counter (OTC) medications within 2 weeks prior to dosing; or have taken functional vitamins, health supplements, or herbal products; or are known to require other medication during the trial period;
- Have consumed excessive amounts of tea, coffee, or caffeinated beverages (average > 8 cups per day, 200 mL per cup) within 3 months prior to screening;
- Have consumed special foods (e.g., grapefruit, grapefruit juice, or food/beverages containing grapefruit juice, chocolate, tobacco, alcohol, caffeinated products, etc.) within 48 hours prior to dosing;
- Have a history of regular alcohol consumption (i.e., > 14 standard units per week within 3 months prior to Screening, where 1 standard unit contains 14 g of alcohol, equivalent to 285 mL of beer, 25 mL of 40% spirit, or 85 mL of wine), or are unable to abstain from alcohol during the trial; or have a positive alcohol breath test;
- Have an average daily smoking history of > 5 cigarettes per day within 3 months prior to Screening, or are unable to abstain from smoking during the trial;
- Have a history of drug abuse or substance use; or have a positive result on drug abuse screening (including MDMA, methamphetamine, morphine, ketamine, and THC acid);
- Are pregnant or lactating females;
- Have difficulty with venous blood sampling, are unable to tolerate venipuncture, or have a history of needle or blood phobia;
- Participants who, in the opinion of the investigator, may be unable to complete the study for other reasons, or who are considered unsuitable for enrollment by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dose 1 Group: SHR-3201 + Placebo
SHR-3201, SHR-3201 Placebo, in Dose 1. |
SHR 3201 injection. SHR 3201 placebo. |
|
Experimental: Dose 2 Group: SHR-3201 + Placebo
SHR-3201, SHR-3201 Placebo, in Dose 2. |
SHR 3201 injection. SHR 3201 placebo. |
|
Experimental: Dose 3 Group: SHR-3201 + Placebo
SHR-3201, SHR-3201 Placebo, in Dose 3. |
SHR 3201 injection. SHR 3201 placebo. |
|
Experimental: Dose 4 Group: SHR-3201 + Placebo
SHR-3201, SHR-3201 Placebo, in Dose 4. |
SHR 3201 injection. SHR 3201 placebo. |
|
Experimental: Dose 5 Group: SHR-3201 + Placebo
SHR-3201, SHR-3201 Placebo, in Dose 5. |
SHR 3201 injection. SHR 3201 placebo. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Adverse events (AEs)
Time Frame: From pre-dose to 36 days post-dose.
|
From pre-dose to 36 days post-dose.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Serum concentration of SHR-3201 after single-dose administration
Time Frame: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Area Under the Concentration (AUC) of SHR-3201 after single administration (AUC0-last, AUC0-inf)
Time Frame: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Time to peak concentration (Tmax)
Time Frame: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Peak concentration (Cmax)
Time Frame: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Elimination half-life (T1/2)
Time Frame: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Clearance (CL)
Time Frame: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Steady-state volume of distribution (Vss)
Time Frame: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Bioavailability of SHR-3201 following subcutaneous administration
Time Frame: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Incidence of anti-drug antibodies (ADA)
Time Frame: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SHR-3201-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.